Brokers Offer Predictions for CRSP FY2026 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for CRISPR Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will earn ($6.73) per share for the year. Cantor Fitzgerald has a "Neutral" rating on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.

Other equities research analysts have also recently issued research reports about the company. JMP Securities restated a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, May 21st. HC Wainwright reissued a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Truist Financial raised their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, February 12th. Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and boosted their price objective for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Finally, Citigroup dropped their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a report on Tuesday, February 18th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $71.75.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded up $0.85 during mid-day trading on Tuesday, reaching $42.94. The company had a trading volume of 3,527,383 shares, compared to its average volume of 1,750,991. The stock's 50-day simple moving average is $36.99 and its 200-day simple moving average is $41.06. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $67.88. The company has a market capitalization of $3.71 billion, a P/E ratio of -9.83 and a beta of 1.75.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. The business's revenue for the quarter was up 71.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.43) earnings per share.

Hedge Funds Weigh In On CRISPR Therapeutics

Large investors have recently bought and sold shares of the business. Kestra Private Wealth Services LLC lifted its position in CRISPR Therapeutics by 1.5% in the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock valued at $812,000 after purchasing an additional 310 shares during the last quarter. Capital Advisors Inc. OK grew its position in CRISPR Therapeutics by 3.2% in the 4th quarter. Capital Advisors Inc. OK now owns 310,270 shares of the company's stock worth $12,212,000 after purchasing an additional 9,681 shares during the last quarter. Van ECK Associates Corp increased its stake in shares of CRISPR Therapeutics by 5,269.3% in the fourth quarter. Van ECK Associates Corp now owns 83,010 shares of the company's stock valued at $3,267,000 after purchasing an additional 81,464 shares during the period. Congress Asset Management Co. raised its holdings in shares of CRISPR Therapeutics by 4.5% during the fourth quarter. Congress Asset Management Co. now owns 68,739 shares of the company's stock valued at $2,706,000 after buying an additional 2,971 shares during the last quarter. Finally, Allworth Financial LP boosted its position in shares of CRISPR Therapeutics by 2,117.4% during the fourth quarter. Allworth Financial LP now owns 15,078 shares of the company's stock worth $593,000 after buying an additional 14,398 shares during the period. Institutional investors own 69.20% of the company's stock.

Insiders Place Their Bets

In other news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the sale, the insider now directly owns 6,068 shares of the company's stock, valued at approximately $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.30% of the stock is owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.